FDA approves Roche’s Tecentriq plus chemotherapy (Abraxane and carboplatin) for the initial treatment of metastatic non-squamous non-small cell lung cancer

Liz Kane
Impactful Strategy

David Linetsky
Point-of-Care Marketing

Frank Burrell
Scientific Storytelling

Amy Giles
Increasing Engagement

Matthew Durham
Omnidynamic Marketing

Joey Cohen
Medication Adherence

Suma Ramadas, PhD
Medical Affairs

Daniel Sontupe
Market Access

Matt Turner
Patient Affordability

Bud Bilanich
Success Coach

Stacey Gandler
Brand Nourishment

Brenda Snow
Authentic Patient Voice

Pat Purcell
Meeting Engagement

Paul Theisen
Patient Acquisition